Yale Professor Blasts Feds For Blocking HCQ

Yale Professor Blasts Feds For Blocking HCQ
Image Screenshot From Anti-propaganda Machine YouTube Video Below.




Amid the coronavirus pandemic, Harvey Risch, an epidemiology professor at Yale School Of Public health, has claimed that the drug hydroxychloroquine with the combination of zinc and antibiotics, can be a highly effective way of treating patients who are at high risk from COVID-19.

According to Risch, there are two stages of illness. It isn’t necessarily true for the treatment procedure which works quickly at the first stage, to work the same way for patients who have reached the serious second stage.

Risch said that it all depends on when the drug Hydroxychloroquine is used. The first stage is a flu-like illness, which is not dangerous and will not kill you. If a high-risk patient begins the treatment procedure quickly, they will be able to get rid of the coronavirus. If not treated, the high-risk patient may reach the life-threatening second stage where the virus causes severe pneumonia and starts affecting the heart. Risch explained this in the Washington Examiner’s Opinion section.

The treatment for people with high risk should be started even before getting the result of the coronavirus test, according to Risch. It is really important to know that low risk patients can survive even without the treatment. What does low risk mean? If one’s age is under 60 and has no chronic illness such as diabetes, obesity, hypertension, cancer, and is not immuno-compromised, that patient is a low-risk person. High-risk means having one or more of these chronic symptoms. If a high-risk patient has any of the coronavirus symptoms, they should start the treatment immediately.

Risch has shown his frustration with the FDA. He said that it’s a serious mistake for the FDA to use in-patient data to block the emergency use of hydroxychloroquine for out-patients. In March, the FDA approved the emergency use of hydroxychloroquine for hospitalized patients. For them, this drug is not as effective as it is for out-patients. If this drug met all the criteria set by the FDA for emergency in-patient use, then it should definitely fulfill all the criteria for out-patient use.




If the drug was widely accepted for its efficiency in treating the coronavirus, no one would stand to make money out of it.

Hydroxychloroquine is an inexpensive and generic medicine. Unlike some profit-making, patented medication which have been promoted as highly effective, Hydroxychloroquine has no financial background and no one can rake in money from it. That’s the reason no one has the impetus to promote this medicine.

Another thing that Risch speculated is that the FDA receives one-third of its funding from different drug companies. There’s a big chance that the FDA was pressured by those companies to be more strict with the handling of hydroxychloroquine. If hydroxychloroquine becomes popular and widely used for treating the coronavirus, the market for expensive patented medicines used in treating coronavirus will diminish significantly.




One thing we can all see is that there has been dirty politics behind the scenes concerning HCQ. Anyone who has spoken of the benefits of this drug is always scrutinized. The Democrats made it a point to ban HCQ because it doesn’t fit into their “science” theory.

These left-wing people are making a bigger mistake by not allowing the use of the OTC drug HCQ to treat the coronavirus. It’s quite obvious that everyone involved against HCQ wants to earn profit from the big pharmaceutical businesses.

In late July, Dr. Anthony Fauci stated, “We know that every single good study — and by good study I mean randomized controlled study in which the data are firm and believable — has shown that hydroxychloroquine is not effective in the treatment of COVID-19.”